Business:
Drugs to regulate hepcidin expression within the body
Drug notes:
DISC-0974 Clin1b/Clin2 anemia of myelofibrosis, Clin0 anemia of CKD, undisclosed; MWTX-003 Clin0 beta-thalassemia, polycythemia vera
About:
Disc Medicine is developing therapies for rare blood diseases. Red blood cells have a characteristic disc shape that facilitates their role in oxygen transport, however, there are millions of patients whose lives are affected by hematologic diseases. Disc medicine is focusing on the fundamentals, heme and iron, that are important for red blood cell function to develop effective therapies. In particular, Disc’s main programs are designed to modulate heme biosynthesis and iron metabolism which is supported by genetic or clinical evidence. Bitopertin, Disc’s lead compound, is an oral, selective inhibitor of glycine transporter 1 and now being tested in Phase 2 clinical trials.
Associate Director, Biologics Drug Product Massachusetts, United States|8 days ago
Associate Director, Biologics Drug Product Watertown, MA|9 days ago
Director, Market Access Marketing & Operations Boston, MA|15 days ago
Director, Market Access Marketing and Operations Watertown, MA|18 days ago
****** ********, ********* ******** & ****** *********, **|38 days ago
Research Operations Manager Watertown, MA|39 days ago
Director, Sales Operations & Training Watertown, MA|39 days ago
Manager, Clinical Data Management Watertown, MA|40 days ago
Join Our Talent Community Watertown, MA|46 days ago
Vice President, Sales Watertown, MA|51 days ago
Manager, Pharmacovigilance Watertown, MA|73 days ago
******* ******* *******, ********* *********, **|86 days ago
Director, Small Molecule Chemical Development Watertown, MA|95 days ago
Senior Director, Patient Services & Distribution Watertown, MA|Not provided
Manager, Medical Information Watertown, MA|Not provided